Premium
Effect of Infliximab and Tocilizumab on Fructose Induced Hypertension and Insulin Resistance in Rats
Author(s) -
Ali Badreldin H.,
Suleimani Yousuf M.,
Abdelrahman Aly M.
Publication year - 2018
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2018.32.1_supplement.838.4
Subject(s) - insulin resistance , medicine , fructose , uric acid , endocrinology , insulin , nitric oxide , chemistry , biochemistry
We investigated the possible protective effect of infliximab (INF), a tumor necrosis factor alpha (TNF‐α) inhibitor and tocilizumab (TOC), an interleukin‐6 (IL6) inhibitor on fructose induced hypertension and insulin resistance in rats. Rats were fed a 60% fructose diet for 8 weeks in the absence or presence of INF (5 mg/kg, i.p., weekly) or TOC (8 mg/kg, i.p., every two weeks) for 4 weeks. Fructose increased blood pressure, plasma insulin, HOMA‐IR, triglycerides, cholesterol, uric acid, aspartate aminotransferase (AST), urea, creatine kinase (CK), nitric oxide and aortic endothelin. Both INF and TOC attenuated fructose induced increase in blood pressure, insulin resistance, plasma nitric oxide and uric acid. TOC reduced the increase in triglycerides and cholesterol. Both drugs did not affect the increase in CK, AST or urea. INF reduced aortic endothelin. Our results showed that both INF and TOC were partially successful in reversing fructose ‐ induced changes. Support or Funding Information This work was supported by a grant from Sultan Qaboos University (IG/MED/PHAR/16/02) This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .